Ozmosi | Peptide yy Drug Profile

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Oral, Intravenous, Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Lactopharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT05110664	APPETITE	N/A	Unknown status	Obesity	2022-08-01	2023-09-06	Primary Endpoints\|Treatments\|Trial Status
NCT05446415	NCT05446415	N/A	Unknown status	Obesity, Morbid\|Type 2 Diabetes	2022-07-07	2024-07-03	Primary Endpoints\|Treatments\|Trial Status
ACTRN12620000917932	CGM-ICU	N/A	Completed	Other	2022-03-15	2024-08-29	Treatments
ACTRN12620000845932	ACTRN12620000845932	N/A	Completed	Healthy Volunteers	2021-12-16	2025-11-30	Treatments
NCT03772067	Mdiet	N/A	Unknown status	Obesity, Metabolically Benign\|Type 2 Diabetes\|Weight Loss	2019-06-20	2020-12-02	Primary Endpoints\|Treatments\|Trial Status
ACTRN12612000376842	ACTRN12612000376842	N/A	Completed	Obesity	2015-08-11	2025-12-06	Treatments
ACTRN12613000728730	ACTRN12613000728730	N/A	Recruiting	Type 2 Diabetes	2015-01-31	2024-08-29	Treatments
ACTRN12612000429853	ACTRN12612000429853	N/A	Completed	Burns, Chemical\|Burns Unspecified\|Fatty Liver	2012-05-21	2024-08-29	Treatments
NCT00940134	INGEAR-1	N/A	Completed	Obesity	2012-01-01	2019-03-18	Treatments
ACTRN12609000853246	ACTRN12609000853246	N/A	Completed	Obesity	2010-03-10	2024-08-29	Treatments
NCT00259233	B208, 2	N/A	Completed	Obesity	None	2019-03-21	Treatments
NCT00259246	B208,1	N/A	Completed	Obesity	None	2019-03-21	Treatments

Recent News Events

Date	Type	Title
12/02/2025	News Article	MetaVia Inc. Announces 1-for-11 Reverse Stock Split
11/10/2025	News Article	MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
11/07/2025	News Article	MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
11/04/2025	News Article	MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
05/09/2024	PubMed	Evaluation of genotoxic damage, production reactive oxygen and nitrogen species in Plasmodium yoelii yoelii exposed to sodium metavanadate.
05/06/2024	PubMed	Development of a Neuropeptide Y-Sensitive Implantable Microelectrode for Continuous Measurements.
04/25/2024	PubMed	Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Peptide yy

Alternative Names: peptide yy, pyy Clinical Status: Inactive Latest Update: 2025-12-02 Latest Update Note: News Article